These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25216369)

  • 1. Animal models of Huntington's disease for translation to the clinic: best practices.
    Menalled L; Brunner D
    Mov Disord; 2014 Sep; 29(11):1375-90. PubMed ID: 25216369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease.
    Howland DS; Munoz-Sanjuan I
    Mov Disord; 2014 Sep; 29(11):1397-403. PubMed ID: 25155258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical models: needed in translation? A Pro/Con debate.
    Philips T; Rothstein JD; Pouladi MA
    Mov Disord; 2014 Sep; 29(11):1391-6. PubMed ID: 25216370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies?
    Gil-Mohapel J; Simpson JM; Ghilan M; Christie BR
    Brain Res; 2011 Aug; 1406():84-105. PubMed ID: 21742312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research.
    Aron Badin R
    Methods Mol Biol; 2018; 1780():267-284. PubMed ID: 29856024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's wrong with my mouse cage? Methodological considerations for modeling lifestyle factors and gene-environment interactions in mice.
    Mo C; Renoir T; Hannan AJ
    J Neurosci Methods; 2016 May; 265():99-108. PubMed ID: 26279343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current clinical management of Huntington's disease.
    Phillips W; Shannon KM; Barker RA
    Mov Disord; 2008 Aug; 23(11):1491-504. PubMed ID: 18581443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?
    Killoran A; Biglan KM
    Mov Disord; 2014 Sep; 29(11):1404-13. PubMed ID: 25164707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drug therapies in Huntington's disease.
    Mason SL; Barker RA
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
    Wood NI; Glynn D; Morton AJ
    Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
    Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
    Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's Disease-Update on Treatments.
    Wyant KJ; Ridder AJ; Dayalu P
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):33. PubMed ID: 28324302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating therapies for Huntington's disease from genetic animal models to clinical trials.
    Hersch SM; Ferrante RJ
    NeuroRx; 2004 Jul; 1(3):298-306. PubMed ID: 15717031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.
    Sampaio C; Borowsky B; Reilmann R
    Mov Disord; 2014 Sep; 29(11):1419-28. PubMed ID: 25216371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive interventions to enhance neural compensation in Huntington's disease.
    Andrews SC; Domínguez JF; Mercieca EC; Georgiou-Karistianis N; Stout JC
    Neurodegener Dis Manag; 2015; 5(2):155-64. PubMed ID: 25894879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity models of Huntington's disease and relevance of hormetic mechanisms: A critical assessment of experimental approaches and strategies.
    Calabrese EJ; Bhatia TN; Calabrese V; Dhawan G; Giordano J; Hanekamp YN; Kapoor R; Kozumbo WJ; Leak RK
    Pharmacol Res; 2019 Dec; 150():104371. PubMed ID: 31415915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.